MEN 14358
Latest Information Update: 10 Apr 2007
Price :
$50 *
At a glance
- Originator Menarini
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Apr 2007 Discontinued - Preclinical for Cancer in Italy (unspecified route)
- 22 May 2003 Preclinical trials in Cancer in Italy (unspecified route)